Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 53:754-762, doi:10.1016/j.jacc.2008.07.073 (Published online 22 December 2008).
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2008.07.073v1
53/9/754    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frankel, D. S.
Right arrow Articles by Meigs, J. B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Frankel, D. S.
Right arrow Articles by Meigs, J. B.
Related Collections
Right arrowRelated Articles

EXPEDITED PUBLICATION

Resistin, Adiponectin, and Risk of Heart Failure

The Framingham Offspring Study

David S. Frankel, MD*, Ramachandran S. Vasan, MD{dagger},{ddagger}, Ralph B. D'Agostino, Sr, PhD{dagger}, Emelia J. Benjamin, MD, ScM{dagger},{ddagger},§, Daniel Levy, MD{dagger},||, Thomas J. Wang, MD{dagger} and James B. Meigs, MD, MPH{dagger},#,*

* Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
{dagger} Framingham Heart Study, Framingham, Massachusetts
{ddagger} Department of Medicine, School of Medicine, Boston University, Boston, Massachusetts
§ Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts
|| National Heart, Lung, and Blood Institute, Bethesda, Maryland
Division of Cardiology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
# General Medicine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts

Manuscript received April 9, 2008; revised manuscript received June 11, 2008, accepted July 1, 2008.

* Reprint requests and correspondence: Dr. James B. Meigs, General Medicine Division, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, Massachusetts 02114 (Email: jmeigs{at}partners.org).

Objectives: We tested the association of the adipokines resistin and adiponectin with incident heart failure.

Background: Abnormal concentrations of adipokines may partially explain the association between obesity and heart failure.

Methods: We related circulating adipokine concentrations to the incidence of heart failure in 2,739 participants in the Framingham Offspring Study.

Results: During 6 years of follow-up, 58 participants developed new-onset heart failure. In proportional hazards models (adjusting for age, sex, blood pressure, antihypertensive treatment, diabetes, smoking, total/high-density lipoprotein cholesterol ratio, prevalent coronary heart disease, valvular heart disease, left ventricular hypertrophy, and estimated glomerular filtration rate) using the lowest third of the resistin distribution as the referent, the hazard ratios for heart failure in the middle and top thirds were 2.89 (95% confidence interval [CI]: 1.05 to 7.92) and 4.01 (95% CI 1.52 to 10.57), respectively (p = 0.004 for trend). Additional adjustment for body mass index, insulin resistance (measured with the homeostasis model), C-reactive protein, and B-type natriuretic peptide did not substantively weaken this association (multivariable hazard ratios 2.62 and 3.74, p = 0.007). In the maximally adjusted model, each SD increment in resistin (7.45 ng/ml) was associated with a 26% increase in heart failure risk (95% CI: 1% to 60%). Concentrations of adiponectin were not associated with heart failure (multivariable hazard ratios 0.87 and 0.97, p = 0.9).

Conclusions: Increased circulating concentrations of resistin were associated with incident heart failure, even after accounting for prevalent coronary heart disease, obesity, and measures of insulin resistance and inflammation. The findings suggest a role for resistin in human disease and a novel pathway to heart failure.

Key Words: heart failure • resistin • adiponectin • adipokines • epidemiology

Abbreviations and Acronyms
  BMI = body mass index
  CHD = coronary heart disease
  CI = confidence interval
  HDL = high-density lipoprotein
  HOMA-IR = insulin resistance measured with the homeostasis model
  HR = hazard ratio
  UACR = urine albumin/creatinine ratio


Related Articles

Novel Risk Factors for Heart Failure: When the Whole May Be Greater Than the Sum of Its Parts
J. Malcolm O. Arnold and Richard E. Gilbert
J. Am. Coll. Cardiol. 2009 53: 763-764. [Full Text] [PDF]

Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A31. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
L. H. Opie and J. Knuuti
The adrenergic-Fatty Acid load in heart failure.
J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1637 - 1646.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. M. O. Arnold and R. E. Gilbert
Novel risk factors for heart failure when the whole may be greater than the sum of its parts.
J. Am. Coll. Cardiol., March 3, 2009; 53(9): 763 - 764.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement